C
Clearnotehealth
Biotech & Life Sciences · San Diego, United States · Founded 2016
Bluestar Genomics Delivering Precision Epigenomic Medicine MoreLess
Bluestar Genomics, now known as ClearNote Health, is a commercial-stage company that specializes in non-invasive cancer detection. The company operates in the healthcare and biotechnology market, with a primary focus on cancer research and diagnostics. They serve a broad client base that includes healthcare providers, cancer patients, and research institutions.
Their business model revolves around the development and commercialization of innovative technologies for cancer detection. They use advanced research and development (R&D) methods to create solutions that prioritize patient needs. Their key offering is a non-invasive cancer detection method, which is a less painful and more convenient alternative to traditional cancer detection procedures.
The company also uses sophisticated data analytics to optimize user experience and improve their services. They collect and analyze data on user behavior and use this information to make improvements. This data-driven approach allows them to provide a more personalized and efficient service to their clients.
In terms of revenue, ClearNote Health likely generates income through the sale of their diagnostic services to healthcare providers and patients. They may also earn revenue from partnerships with other healthcare and research institutions, and possibly from referral commission fees.
Keywords: Non-invasive cancer detection, Healthcare, Biotechnology, Research and Development, Patient-centric, Data Analytics, User Experience, Diagnostic Services, Partnerships, Referral Commissions.
Company overview
Clearnotehealth company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- San Diego, United States
- Employees
- 57
- Open positions
- None listed
- Dealroom signal
- 55.4
Valuation & funding
Clearnotehealth funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES DOther financing | Jun 2026 | $52M | $350M | Mattias Westman · Stephen Quake | ↗ |
| SERIES COther financing | May 2021 | $70M | $280M | Mattias Westman · Pathology Asia Holdings | — |
| SPINOUTOther financing | Jan 2016 | $0 | — | Stanford University | — |
Growth signals
Clearnotehealth website traffic
Latest recorded traffic for Clearnotehealth is 5.9K monthly website visits. Clearnotehealth's team grew 14% over the past year.
Comparisons
Clearnotehealth compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Clearnotehealth's talent
Source: Dealroom Talent Intelligence.
Investors
4 investors on Clearnotehealth's cap table
Sourced from Dealroom's funding and investor records.




Global footprint
Where Clearnotehealth has talent and traffic
team presence
In the news
Latest news about Clearnotehealth
Recent press, funding announcements, and product moves mentioning Clearnotehealth — open to read from the original sources.
Market sentiment
What the market is saying about Clearnotehealth
An AI-synthesized read of the highest-engagement posts about Clearnotehealth on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Clearnotehealth’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.






